

#NANSRFS: VISUAL ABSTRACT SERIES


IDDS VS. CMM FOR REFRACTORY CANCER PAIN

STUDY POPULATION



Prospective, Randomized, Multi-center

INTERVENTION



VS.



101 patients underwent IDDS 4 week follow up, n= 73 99 patients had CMM 4 week follow up, n=75

REDUCTION
IN VAS
SCORES
IDDS= 51.5%
CMM = 39%

PAIN

TOXICITY

REDUCTION IN TOXICITY IDDS= 50.3% CMM= 17%

IMPROVED SURVIVAL

IDDS= 53.9% CMM = 37.2%



SURVIVAL

CMM + IDDS > CMM ALONE IN REDUCING PAIN & TOXICITY AND INCREASING SURVIVAL





Smith et al. Journal of Clinical Oncology Oct, 2002 www.ncbi.nlm.nih.gov/pubmed/12351602